NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Kiniksa reported strong Q4 2024 financial results driven by ARCALYST sales, announced the development program for KPL-387, and planned to discontinue abiprubart development in Sjögren’s Disease.
Kiniksa Pharmaceuticals reported strong commercial execution in 2024, resulting in 79% year-over-year ARCALYST sales growth to $417.0 million. The company is planning to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 and discontinue the development of abiprubart in Sjögren’s Disease.
- ARCALYST Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively
- ARCALYST 2025 net product revenue expected to be $560 - $580 million
- KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026
- Abiprubart development in Sjögren’s Disease to be discontinued
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$123M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa expects ARCALYST 2025 net product revenue to be between $560 - $580 million and the current operating plan is expected to remain cash flow positive on an annual basis.
Tailwinds
- ARCALYST 2025 net product revenue expected to be $560 - $580 million
- KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025
- Phase 2 data expected in 2H 2026 for KPL-387
- Focus on cardiovascular indications
- Current operating plan expected to remain cash flow positive on an annual basis
Headwinds
- Abiprubart development in Sjögren’s Disease to be discontinued
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials
- Potential undesirable side effects caused by products and product candidates
- Reliance on third parties as the sole source of supply of the drug substance and drug product
- Raw material, important ancillary product and drug substance and/or drug product shortages
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro